249 related articles for article (PubMed ID: 31686856)
1. Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy.
Girard J; Reneau J; Devata S; Wilcox RA; Kaminski MS; Mercer J; Carty S; Phillips TJ
Onco Targets Ther; 2019; 12():8003-8014. PubMed ID: 31686856
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma.
Lu J; Do B; Primeaux B
J Oncol Pharm Pract; 2024 Feb; ():10781552241232331. PubMed ID: 38356268
[TBL] [Abstract][Full Text] [Related]
3. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Owen C; Berinstein NL; Christofides A; Sehn LH
Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
[TBL] [Abstract][Full Text] [Related]
4. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
5. Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.
Abbas HA; Wierda WG
Front Oncol; 2021; 11():668162. PubMed ID: 34055635
[TBL] [Abstract][Full Text] [Related]
6. Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.
Aalipour A; Advani RH
Ther Adv Hematol; 2014 Aug; 5(4):121-33. PubMed ID: 25360238
[TBL] [Abstract][Full Text] [Related]
7. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
8. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Danilov AV; Persky DO
Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States.
Alrawashdh N; McBride A; Slack M; Persky D; Andritsos L; Abraham I
J Manag Care Spec Pharm; 2022 Apr; 28(4):390-400. PubMed ID: 35332792
[No Abstract] [Full Text] [Related]
10. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.
Munoz JL; Wang Y; Jain P; Wang M
Curr Oncol Rep; 2022 Oct; 24(10):1299-1311. PubMed ID: 35596920
[TBL] [Abstract][Full Text] [Related]
11. The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
Hanna KS; Campbell M; Husak A; Sturm S
J Oncol Pharm Pract; 2020 Jul; 26(5):1190-1199. PubMed ID: 32279595
[TBL] [Abstract][Full Text] [Related]
12. Use of acalabrutinib in patients with mantle cell lymphoma.
Awan FT; Jurczak W
Expert Rev Hematol; 2018 Jun; 11(6):495-502. PubMed ID: 29737219
[TBL] [Abstract][Full Text] [Related]
13. Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.
Davis DD; Ohana Z; Pham HM
J Oncol Pharm Pract; 2024 Jan; 30(1):182-188. PubMed ID: 38043933
[TBL] [Abstract][Full Text] [Related]
14. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Bond DA; Alinari L; Maddocks K
Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
[TBL] [Abstract][Full Text] [Related]
15. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
Muñoz J; Wang Y; Jain P; Wang M
Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
[TBL] [Abstract][Full Text] [Related]
16. Acalabrutinib for adults with mantle cell lymphoma.
Jurczak W; Długosz-Danecka M; Wang M
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):179-187. PubMed ID: 30638402
[TBL] [Abstract][Full Text] [Related]
17. An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma.
Morabito F; Recchia AG; Vigna E; Botta C; Skafi M; Abu-Rayyan M; Atrash M; Galimberti S; Morabito L; Al-Janazreh H; Martino M; Cutrona G; Gentile M
Expert Opin Pharmacother; 2020 Jan; 21(1):29-38. PubMed ID: 31738609
[No Abstract] [Full Text] [Related]
18. Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data.
Isaac K; Mato AR
Cancer Manag Res; 2020; 12():2079-2085. PubMed ID: 32256115
[TBL] [Abstract][Full Text] [Related]
19. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
20. SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.
Romancik JT; Gerber DG; Zhuang T; Cohen JB
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):557-565. PubMed ID: 35123927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
